​

Funding Round

Series C - Amolyt Pharma

Series C - Amolyt Pharma

Investment Firm

Overview

Amolyt Pharma specializes in peptides for the treatment of rare endocrine and metabolic disorders.

Announced Date

Jan 06, 2023

Funding Type

Series C

Highlights

Location

Europe

Social

Investor Lead

Sofinnova Partners

Sofinnova Partners

Sofinnova Partners is a early_stage_venture and late_stage_venture and seed firm.

Intermediate Capital Group

Intermediate Capital Group

Intermediate Capital Group is a debt and private_equity firm.

Participant Investors

16

Investor Name
Participant InvestorTurenne Capital
Participant InvestorSofinnova Partners
Participant InvestorBpifrance
Participant InvestorEQT Life Sciences
Participant InvestorAndera Partners

Round Details and Background

Amolyt Pharma raised $138629699 on 2023-01-06 in Series C

Amolyt Pharma specializes in peptides for the treatment of rare endocrine and metabolic disorders.

Company Funding History

9

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Sep 16, 2021
Series B - Amolyt Pharma
13-80.0M
Jan 06, 2023
Series C - Amolyt Pharma
16-138.6M
Sep 10, 2014
Series A - Amolyt Pharma
1-6.5M
Jun 04, 2012
Venture Round - Amolyt Pharma
2-4.1M

Recent Activity

There is no recent news or activity for this profile.